ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "citrullination"

  • Abstract Number: 0062 • ACR Convergence 2024

    Pro-Fibrotic Effects of Malondialdehyde-Acetaldehyde-Adducted and/or Citrullinated Proteins on Macrophages and Human Lung Fibroblasts

    Lauren Klingemann1, Nozima Aripova1, Nigina Aripova2, Michael Duryee1, Carlos Hunter1, Jill Poole1, Bryant England1, Ted Mikuls1 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2WUSTL, St. Louis, MO

    Background/Purpose: Clinically evident rheumatoid arthritis-associated interstitial lung disease (RA-ILD) affects approximately 10-15% of patients with rheumatoid arthritis (RA) and accounts for the most overrepresented cause…
  • Abstract Number: 0065 • ACR Convergence 2024

    Evidence of Membranolytic Targeting and Intracellular Citrullinationin Neutrophils Isolated from Patients with Rheumatoid Arthritis

    Neela Fatemeh Moadab1, Tal Gazitt2, Rayan Najjar1, Ethan Le1, J Lee Nelson3, Vijay Joshua4, Keith Elkon1, Caroline Grönwall4 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2Carmel Hospital, Haifa, Israel, 3University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) are diagnostic for rheumatoid arthritis (RA). The antigens recognized by these autoantibodies are produced by protein arginine deiminases (PADs), particularly…
  • Abstract Number: 1846 • ACR Convergence 2024

    Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis

    Amy Anderson1, Henrique de Paula Lemos1, Hendrik Nel2, Sofia Sorbet Santiago1, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Jasmine Sim1, Andrew Melville4, Stefan Siebert4, Iain McInnes5, Carl Goodyear4, Catharien Hilkens1, Andrew Filer6, Karim Raza6, Christopher Buckley7, Hugh Reid8, Kenneth Baker1, Arthur Pratt3, Jamie Rossjohn8, Ranjeny Thomas9 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 5University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 6Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 7Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 8Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, 9University of Queensland, Brisbane, Australia

    Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
  • Abstract Number: 1858 • ACR Convergence 2024

    Co-modification of Citrullinated Proteins with Malondialdehyde-Acetaldehyde Leads to Amplified T Cell Responses and Increased Disease-specific Autoantibody Concentrations

    Breanna Butler1, Wenxian Zhou2, Michael Duryee1, Nozima Aripova1, Engle Sharp1, Carlos Hunter1, Bridget Kramer1, Harlan Sayles1, James O'Dell1, Geoffrey Thiele1, Bryant England1, Joshua Baker3, Andreas Reimold4, Gail Kerr5 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE, 3University of Pennsylvania, Philadelphia, PA, 4Dallas VA Medical Center, Dallas, TX, 5Washington DC VAMC/Georgetown and Howard Universities, Washington, DC

    Background/Purpose: Anti-citrullinated protein antibody (ACPA) is highly specific to rheumatoid arthritis (RA). Beyond citrullination, other post-translational protein modifications including malondialdehyde-acetaldehyde (MAA) are targeted by T…
  • Abstract Number: 0045 • ACR Convergence 2024

    Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins

    Khushali Trivedi1, Clarissa Klenke2, Jun Kim1, Jeba Atkia Maisha2, Alina Sememenko1, XIAOBO MENG2, Mario Navarrete1, Hani El-Gabalawy2 and Liam O'Neil2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
  • Abstract Number: 0046 • ACR Convergence 2024

    Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies

    Jeba Atkia Maisha1, Alina Sememenko2, Jun Kim2, Mario Navarrete2, XIAOBO MENG1, Hani El-Gabalawy1 and Liam O'Neil1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…
  • Abstract Number: L08 • ACR Convergence 2023

    Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation

    Leonie Middelink1, Renato Chirivi2, Helmuth van Es2, Eric Meldrum2, Peter van Zandvoort2, Tirza Bruurmijn2, Matthijs Moerland3 and Patrick Round2, 1Middelinc., Utrecht, Netherlands, 2Citryll BV, Oss, Netherlands, 3CHDR, Leiden, Netherlands

    Background/Purpose: Aberrant Neutrophil Extracellular Traps (NETs) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases such as Rheumatoid arthritis (RA) Hidradenitis suppurativa (HS),…
  • Abstract Number: 0045 • ACR Convergence 2023

    Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases

    Min Yang1, song feng1, yuling wen1, Xiaoming ren1, Huijuan Li1, lili yao1, Zhi xie2 and Wenge zhong1, 1Regor Therapeutics, Shanghai, China, 2Regor Pharmaceuticals, Inc., San Francisco, CA

    Background/Purpose: Protein arginine deiminases (PAD) 4 is an enzyme that catalyzes the conversion of protein-embedded arginine to citrulline. It is essential for neutrophil extracellular traps…
  • Abstract Number: 0050 • ACR Convergence 2023

    Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease

    Maarten van der Linden1, Sangeeta Kumari1, Daphne Montizaan1, Stephanie van Dalen1, Annemarie Kip1, Martyn FOSTER2, Inge Reinieren1, Elsa Neubert3, Luise Erpenbeck4, Tirza Bruurmijn1, Peter van Zandvoort1, Paul Vink1, Eric Meldrum5, Helmuth van Es1 and Renato Chirivi1, 1Citryll BV, Oss, Netherlands, 2Experimental Pathology Consultancy, Benfleet, United Kingdom, 3Leiden Academic Centre for Drug Research, Leiden, Netherlands, 4University Medical Center Münster, General Dermatology and Venereology, Münster, Germany, 5Citryll BV, Basel, Switzerland

    Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of multiple inflammatory and autoimmune diseases (Chirivi et al., 2021; DOI: 10.1038/s41423-020-0381-3). Targeting the NETosis pathway…
  • Abstract Number: 0423 • ACR Convergence 2023

    Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis

    Sara Charmsaz1, Jeff Tracy1, Elizabeth Whalen1, John Bui1, Anne-Renee van der Vuurst de Vries1, Vivianne Malmström2 and Michelle Blake1, 1Sonoma Biotherapeutics, Seattle, WA, 2Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…
  • Abstract Number: 1727 • ACR Convergence 2023

    Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice

    Sheri Saunders, Garth Blackler, Patti Kiser, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

    Background/Purpose: Most rheumatoid arthritis (RA) patients express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated (also known as carbamylated) peptides. Homocitrulline and citrulline are…
  • Abstract Number: 1742 • ACR Convergence 2023

    Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA

    Rachna Talluri1, Sudeshna Sen2, Timothy Wilson3, Adam Savage4, Mark Gillespie4, Tom Bumol4, Marie Feser1, Jill Norri5, Michael Holer1, kevin Deane1, Paul Thompson2 and Kristen Demoruelle1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Massachusetts Chan Medical School, Worcester, MA, 3Thomas Jefferson University, Philadelphia, PA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Denver, CO

    Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
  • Abstract Number: 1748 • ACR Convergence 2023

    Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies

    S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
  • Abstract Number: 1764 • ACR Convergence 2023

    Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease

    Breanna Butler1, Jill Poole1, Michael Duryee1, Nozima Aripova1, Carlos Hunter1, Bridget Kramer1, James O'Dell1, Geoffrey Thiele1, Bryant England1 and Ted R Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
  • Abstract Number: 1775 • ACR Convergence 2023

    The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline

    Jack Mordeson1, Nozima Aripova1, Michael Duryee1, James O'Dell1, Bryant England1, Daniel Anderson1, Ted R Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90%…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology